670 results about "Immunity response" patented technology

A federated distributed computational system enables secure biological data analysis and genomic medicine with enhanced oncological therapy capabilities. The system implements patient-specific tumor-on-a-chip analysis through microfluidic control systems and cellular heterogeneity preservation, while integrating fluorescence-enhanced diagnostics using CRISPR-LNP targeting and robotic surgical navigation. The architecture coordinates spatiotemporal analysis of gene therapy delivery through molecular imaging and immune response tracking, and implements bridge RNA integration with multi-target synchronization. Treatment selection is optimized through multi-criteria scoring and patient-specific simulation modeling. Each federated node contains a local processing unit for biological data analysis, privacy preservation protocols, and a hierarchical knowledge graph structure. The system implements cross-species genetic analysis, environmental response modeling, and multi-scale tensor-based data integration, enabling research institutions to collaborate on complex, large-scale biological analyses while maintaining strict data privacy controls.

The invention relates to the technical field of deep processing of cattle spleen, in particular to cattle spleen active polypeptide capable of enhancing immunity and a preparation method and a functional product thereof. The preparation method comprises the following steps: mincing cattle spleen, adding water, uniformly mixing, heating and curing; adding bacillus licheniformis alkaline protease to carry out hydrolysis for the first time; adding papain and bacillus subtilis flavourzyme into the first hydrolysate to carry out hydrolysis for the second time; and performing enzyme deactivation on the second hydrolysate, and sequentially performing fishy smell removal, decolorization, filtration, concentration and drying treatment to obtain the cattle spleen polypeptide. The cattle spleen polypeptide prepared by the invention can obviously enhance the immune response of a body and play a role in enhancing immunity, can be applied to a functional product for enhancing immunity as a functional factor, has the advantages of low equipment requirement, simple process, easiness in operation, high extraction efficiency and the like, is suitable for industrial production, and has a wide application prospect. The scheme of the invention has good application and economic prospects.

The present invention relates to a method for producing a canine atopic dermatitis animal model, a canine atopic dermatitis animal model produced thereby, and a use thereof. According to the present invention, a canine atopic dermatitis animal model is produced by skin stimulation on a dog through epicutaneous sensitization with ovalbumin at a concentration of 1 to 5 mg / ml once daily for 1 to 2 weeks and then with ovalbumin at a concentration of 1 to 5 mg / ml once daily for 2 to 8 weeks. The resulting animal model exhibits clinical symptoms of atopic dermatitis, changes in relevant factors such as increased expression levels of IgE and CCL17, and elevated expression levels of Th2-related cytokines IL-4, IL-31, and IL-13. Therefore, this invention enables the establishment of a standardized animal model for symptoms and Th2 immune responses appearing upon the onset of atopic dermatitis, and the model can be used in clinical studies for screening candidate agents for the prevention, alleviation, or treatment of atopic dermatitis.

The present invention discloses a strain of Lactobacillus paracasei that simultaneously activates immune regulation and antioxidant pathways to alleviate vaginitis, belonging to the field of microbial technology. The present invention screened and obtained a strain of Lactobacillus paracasei CCFM1316, which has the effect of repairing related symptoms such as immune disorders and oxidative damage caused by vaginitis, specifically embodied in: reducing cellular NF-κB mRNA expression and cell supernatant IL-1β content, improving mouse vaginal immune response, enhancing mouse vaginal antioxidant capacity, improving mouse vaginal pathological manifestations and reducing pathogenic bacteria load. It reduces the mouse vaginal Gardnerella load and improves mouse vaginal pathological manifestations; therefore, Lactobacillus paracasei CCFM1316 has great application prospects in products that improve and repair immune disorders and oxidative damage problems caused by vaginitis.

The invention belongs to the field of molecular biology, and particularly relates to application of OsDOF3 protein or a coding gene thereof to improvement of rice broad-spectrum disease resistance and regulation of agronomic traits. According to the application, an OsDOF3 knockout mutant and an overexpression transgenic line are constructed under the background of susceptible rice, resistance phenotype analysis is performed by inoculating various pathogenic bacteria (including pyricularia oryzae, rhizoctonia solani and bacterial blight), and it is proved that OsDOF3 participates in regulation and control of an immunoreaction pathway of rice to fungal diseases (rice blast and sheath blight) and bacterial diseases (bacterial blight). Meanwhile, the application also finds that after a strong promoter ubi is adopted for driving, an overexpression material of the OsDOF3 is shorter than that of a wild plant, and the OsDOF3 influences normal growth and development of rice while stimulating plant immune response. The invention provides important gene resources and molecular theoretical basis for developing a new variety of broad-spectrum disease-resistant rice.

Treatment of damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) is provided by delivering specialized pulsed electric field (PEF) energy to target tissue areas in a specific dose so as to obtain a superior outcome. The PEF energy and delivery has been optimized to provide advanced treatment of target tissue areas, including destruction of undesired tissue and generation of improved inflammatory and immune responses. These various types of treatment are controlled by a variety of factors including the electrode geometry, the dose of PEF energy delivered, the time the energy is delivered over, and the waveform of the PEF energy itself. The PEF energy is delivered in the form a dose which is considered to be one application of the specialized energy. Each dose creates a lesion in the target tissue area.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

The invention discloses preparation and application of dual-network hydrogel. The dual-network hydrogel comprises the following components: (Z1) a spinal cord acellular matrix network DSM formed by self-assembly of a spinal cord acellular matrix dSECM; and (Z2) a metal-polyphenol network MPN formed by coordination of metal ions and polyphenols; wherein the DSM and the MPN are cross-linked through hydrogen bonds to jointly form a double-network structure. DSM provides a microenvironment suitable for cell survival and growth for the dual-network hydrogel and induces stem cells to differentiate into neurons, and MPN provides the dual-network hydrogel with biological effects of inhibiting inflammation and accumulation of reactive oxygen species (ROS). The dual-network hydrogel has the advantages of the two components, the active component neurotrophic factor and the inhibitor loaded on the dual-network hydrogel can regulate and control immune response after SCI, improve neuroinflammation microenvironment and promote nerve repair, and a new strategy is provided for in-situ tissue repair of SCI.

The invention belongs to the technical field of agricultural biological control, and particularly relates to bacillus velezensis, a biological preparation and application of the bacillus velezensis in plant disease prevention and growth promotion. The bacillus velezensis is preserved in the China Center for Type Culture Collection, the preservation number of the bacillus velezensis is CCTCC NO: M 2025613, and the bacillus velezensis is classified and named as bacillus velezensis B54. Experiments show that the bacillus velezensis and the biological preparation thereof provided by the invention have broad-spectrum antagonistic activity, can effectively inhibit growth of pathogenic bacteria such as pythium spp and fusarium spp, induce plants to generate immune response, remarkably reduce the incidence rate of root rot and blight of the plants, can also generate plant growth stimulants, improve the development of plant root systems, improve the growth of the plant root systems and promote the growth of the plant root systems. The crop yield and quality are improved.

Systems and methods to assess immune receptor sequences can incorporate a language model to yield embedded representations and classification of immune status. Classification systems and method can include assessment of embedded immune receptor sequence representations that account for isotype or V(D)J gene segment selection. Systems and methods to assess immunity status can incorporate one or more classifiers to predict immune status.

The invention belongs to the technical field of biomedicine, and discloses a nano-particle for enhancing radioimmunotherapy effect through cascade reaction and application of the nano-particle, a preparation method of the nano-particle comprises the following steps: S1, synthesis of ZnO2; the preparation method comprises the following steps: dissolving ZnCl2 and PVP in absolute ethyl alcohol, adding ammonia water and H2O2, after the reaction is completed, collecting precipitates, washing, and dispersing the precipitates in absolute ethyl alcohol to prepare ZnO2; and S2, synthesis of ZnO2 (at) Cu: resuspending ZnO2 in water, sequentially adding ammonia water, a PAA solution, IPA, dopamine hydrochloride and a CuCl2 solution, stirring in a nitrogen atmosphere, centrifuging, washing with ethanol, and drying in vacuum to obtain the ZnO2 (at) Cu nano-particles, namely the nano-particles. According to the nanoparticles, the radiotherapy effect is enhanced through cascade reaction, copper death is induced, immune response is activated, effective treatment on tumors is achieved, and the problems of radiotherapy resistance and immunosuppressive tumor microenvironment are solved.

The invention relates to the field of veterinary vaccines, in particular to a porcine pseudorabies virus antigen, a porcine pseudorabies subunit vaccine as well as a preparation method and application of the porcine pseudorabies virus antigen and the porcine pseudorabies subunit vaccine. The porcine pseudorabies virus antigen is porcine pseudorabies virus gD protein, and the amino acid sequence of the porcine pseudorabies virus gD protein is as shown in SEQ ID NO: 1. The porcine pseudorabies subunit vaccine prepared from the porcine pseudorabies virus antigen is simple in preparation method, high in neutralizing antibody value, strong in antigen immunity, capable of effectively activating immune response of a body and capable of playing a good immune protection role on porcine pseudorabies.

The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

The invention provides an application of linoleic acid in preparation of a feed for relieving fish salinity stress. According to the application of the linoleic acid in preparation of the feed for relieving the salinity stress of the fishes, related experiments verify that the addition of the linoleic acid enhances the overall tolerance of the fishes to the salinity stress, and under the stress environment that the salinity continuously rises, the stress resistance of the fishes to the salinity stress is improved. Fish has better growth performance, lower physiological stress level, stronger antioxidant ability and immune response and healthier tissue structure, and is beneficial to increase of culture benefits of freshwater fish and marine fish.

This invention is directed to compositions comprising curcumin extract and pomegranate extract, and methods of improving immune response with the compositions. The compositions may be administered as a prebiotic and / or a dietary supplement.

The invention relates to the technical field of veterinary biological products, and particularly provides a porcine epidemic diarrhea virus S protein and related products. The amino acid sequence of the porcine epidemic diarrhea virus S protein fragment is as shown in SEQ ID NO.4. The trimer S protein is constructed by fusing a trimer tag at the C terminal of a protective antigen in a truncated form of the porcine epidemic diarrhea virus S protein. After expression and purification, immunogenicity is judged through animal evaluation, and it is verified that the vaccine prepared from the trimer S protein has the advantages of being high in safety, good in immunogenicity, stable in batches, capable of inducing piglets to generate good immunoreaction and the like, and porcine epidemic diarrhea can be effectively treated or prevented.

The invention discloses an application of a training immune agonist in preparation of a drug for sensitizing radiotherapy treatment of tumors, and researches show that the training immune agonist significantly activates immune response of a body by promoting expression of inflammatory cytokines, enhancing phagocytic ability of macrophages, recruiting immune cells and amplifying an immune activation effect, so that the immune response of the body is enhanced. The sensitivity of tumor cells to radiotherapy is improved, and a dual mechanism of'radiotherapy sensitization-immune synergy 'is formed, so that the bottleneck of the traditional radiotherapy curative effect is broken through, the local control rate of radiotherapy is improved, and the recurrence risk is reduced. Experiments prove that the training immune agonist combined with radiotherapy has a remarkable treatment effect on various highly invasive tumors (such as brain glioma and lung cancer brain metastasis) and common malignant tumors (such as colon cancer and lung cancer), and shows wide applicability. The invention provides a new combined therapy direction for tumor treatment, is expected to improve the prognosis of patients, prolong the lifetime and improve the life quality, and has important clinical transformation value.

The invention relates to double-layer hydrogel for scar-free corneal injury repair and a preparation method of the double-layer hydrogel. The preparation method comprises the following steps: (1) synthesizing oxidized polysaccharide and a sulfhydrylated polymer; the method comprises the following steps: oxidizing polysaccharide by taking NaIO4 as an oxidizing agent to obtain oxidized polysaccharide; wherein the oxidized polysaccharide is negatively charged; the preparation method comprises the following steps: modifying an amino-containing antibacterial polymer by using cysteine to obtain a sulfhydrylated polymer; (2) preparing bottom layer hydrogel; amino of the multi-arm polyethylene glycol and oxidized polysaccharide are subjected to a Schiff base reaction, and amino of the multi-arm polyethylene glycol and a multi-arm polyethylene glycol derivative are subjected to a cross-linking reaction, so that bottom-layer hydrogel is formed; wherein the multi-arm polyethylene glycol derivative has a group crosslinked with an amino group; (3) preparing double-layer hydrogel; and spraying the sulfhydrylation polymer on the bottom layer hydrogel, and carrying out UV illumination to obtain the double-layer hydrogel. According to the double-layer hydrogel disclosed by the invention, the purposes of resisting bacterial infection, regulating cascade immunoreaction, reducing scar formation and recovering cornea transparency are achieved through the cooperation of structural design, a biological mechanism and a time sequence.

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARC™).

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The invention relates to the field of image recognition, in particular to an adrenal metastatic tumor prediction analysis method and system based on image recognition. The method comprises the following steps: acquiring PET-CT monitoring images of the adrenal gland of a patient at a plurality of time points, performing metastatic tumor visual detection at one time point by one time point, and extracting metastatic tumor bounding boxes at the plurality of time points; performing surrounding tissue microenvironment dynamic fluctuation analysis and boundary immune influence degree evaluation according to the metastatic tumor bounding box, and constructing a multi-cycle immune reaction intensity diagram; performing metastatic tumor change trend evolution on the metastatic tumor bounding box to obtain metastatic tumor image change trend charts at different time points; and performing peripheral tissue texture feature difference identification according to the metastatic tumor bounding box so as to extract potential tumor metastatic cells. According to the method, the future change of the metastatic tumor is accurately predicted through dynamic prediction of the development trend of the adrenal metastatic tumor, and more intuitive metastatic tumor change conditions at different time points are provided.

The invention provides application of lactobacillus rhamnosus GOLDGUT-M520 or a composition of the lactobacillus rhamnosus GOLDGUT-M520 in preparation of a product for enhancing the immunity of an organism. The lactobacillus rhamnosus GOLDGUT-M520 has the function of enhancing the immunity in both a viable form and an inactivated form of the lactobacillus rhamnosus GOLDGUT-M520. The lactobacillus rhamnosus GOLDGUT-M520 has a good antibacterial capability on escherichia coli and staphylococcus aureus which are pathogenic to intestinal tracts, and is beneficial to enhancing a chemical barrier in an innate immune barrier; the strain can improve the phagocytic activity of macrophages and enhance the innate immune response; the strain can improve the T cell proportion, the B cell proportion and the immune globulin level in mesenteric lymph nodes of immunocompromised mice, and can enhance adaptive immune response. The lactobacillus rhamnosus GOLDGUT-M520 can comprehensively play a role in enhancing immunity, and meanwhile, the inherent immune barrier, the inherent immune response and the adaptive immune response are enhanced.

The embodiment of the invention discloses a recombinant III-type humanized collagen as well as a preparation method and application thereof. The amino acid sequence of the recombinant III-type humanized collagen is shown as SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3. The recombinant III-type humanized collagen has the advantages that the recombinant III-type humanized collagen can be used for preparing the recombinant III-type humanized collagen; the recombinant III-type humanized collagen provided by the invention has the activity of promoting cell adhesion, the amino acid sequence of the recombinant III-type humanized collagen is selected from the amino acid sequence of natural collagen, and the recombinant III-type humanized collagen does not generate immune response when being applied to a human body. The characteristic that corynebacterium glutamicum does not secrete endotoxin is utilized, the preparation method is simple, the product can meet the requirements of food, cosmetics, medical instruments and drugs without complex separation, and reference is provided for low-cost industrial production.

The present invention relates to a recombinant chimeric antigen targeting poxvirus (particularly monkeypox virus), a subunit vaccine thereof, and its application. The recombinant chimeric antigen of the present invention comprises two immunogens arranged in a specific manner: monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment) and monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), which can stimulate immune responses against two infectious virus particles: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently stimulating specific immune protection against monkeypox virus. In addition, the poxvirus vaccine of the present invention also has good safety, rapid responsiveness and production capacity support, and has excellent clinical application prospects.

The invention relates to recombinant bacillus subtilis for displaying PRRSV ER protein on spore surfaces, a construction method and application. The recombinant bacillus subtilis is obtained by constructing a recombinant vector which takes spore capsid protein CotB as anchoring protein and displays PRRSV ER protein on the surface by using a genetic engineering method on the basis of an integrated plasmid pDG364, and transforming the recombinant vector into wild bacillus subtilis 168 by using a chemical transformation method, and has genetic stability; and loss in the passage process is avoided. According to the strain, antigen protein is directly displayed on the surfaces of spores, crushing is not needed, animals can be immunized through direct material mixing or water drinking, and the tedious process of large-scale injection is avoided. And due to the good stress resistance of the spores, the strain is easy to store and transport, and the cost is remarkably reduced. The strain can induce specific immune response, provides a new way for prevention and treatment of PRRSV, and is suitable for development of commercial vaccines.

The invention discloses a PRP (platelet-rich plasma) stem cell exosome chitosan composition as well as a preparation method and application thereof. The PRP stem cell exosome chitosan composition comprises the following components: activated platelet-rich plasma, stem cell exosome and chitosan. The preparation method of the composite gel comprises the following steps: adding chitosan into a suspension containing activated platelet-rich plasma and stem cell exosome, uniformly mixing, adding a povidone suspending aid, oscillating to form a stable suspension state, adjusting the pH value to 7.5-7.8, mixing with thrombin and a calcium agent, stirring in a dark place, and solidifying to form a gelatinous substance, thereby obtaining the composite gel. The platelet-rich plasma-stem cell exosome-chitosan composite gel is obtained. The composition and the composite gel can promote microvascular endothelial cell regeneration and recover normal vascular endothelial morphology and functions; skin regeneration is promoted; broad-spectrum bacteriostasis and lipid reduction are realized, and local inflammation and immune response are inhibited.

The present invention belongs to the field of bioelectrode technology, and specifically relates to an injectable soft bioelectrode hydrogel and its preparation method and application. The preparation method includes preparing an E-A complex and preparing a hydrogel. The hydrogel of the present invention is used to prepare an injectable soft bioelectrode, and the hydrogel is directly injected into the target tissue site through a needle to form a flexible and well-adhesive electrical stimulation interface, which significantly improves the accuracy and stability of electrical stimulation. The hydrogel composition principle and preparation method make it easier to regulate and micro-precisely inject according to different human body parts or clinical needs. Implanting the hydrogel into acupuncture points or other specific tissue sites and applying electrical stimulation can effectively avoid local tissue trauma and immune overreaction caused by traditional hard electrodes. For example, for pancreatic cancer, the electrode of the present invention can achieve more controllable and continuous electrical stimulation, and has the potential to regulate local immune response and inflammation levels, providing a safer and more cost-effective new treatment strategy for clinical diagnosis and treatment.

The invention relates to the technical field of biological medicines, in particular to application of bifidobacterium longum subsp. Infantis in prevention and / or treatment of allergic rhinitis. Researches find that the Bifidobacterium longum subsp.infantis can improve inflammatory response, relieve symptoms of allergic rhinitis of mice, inhibit immune response caused by the allergic rhinitis, inhibit the inflammatory response caused by the allergic rhinitis and / or repair nasal mucosa injury caused by the allergic rhinitis, and the Bifidobacterium longum subsp.infantis can be used for treating the allergic rhinitis. The compound has a huge application prospect in preparation of products for preventing and / or treating allergic rhinitis.

The invention discloses a cell interaction identification method based on cell space transcriptome data, which comprises the following steps: constructing cell pairs according to cell space proximity, and calculating an interaction signal matrix and space information of each pair of cells by combining a ligand-receptor database; then generating cell pair embedding representation by using a graph neural network, calculating the similarity between cell pairs, and calculating the similarity between cells based on a gene expression matrix; updating the similarity matrix through iteration until convergence to obtain a final similarity matrix between cells and between cell pairs; and clustering the similarity matrix, and constructing a cell type and cell pair type model, thereby realizing accurate cell interaction identification. According to the method, space and expression information can be fully utilized, inter-cell heterogeneity and context specificity interaction can be captured, the analysis precision and biological authenticity of a cell communication network are improved, and an effective tool is provided for research on tissue development, disease mechanisms, immune response and the like.

The invention belongs to the technical field of biology, and discloses a preparation method and application of a recombinant adeno-associated virus WNT9B. The recombinant adeno-associated virus WNT9B is obtained by taking an adeno-associated virus (AAV) as a vector to carry a recombinant Wnt9b gene, and compared with an adenovirus vector which has been clinically applied, the recombinant adeno-associated virus WNT9B has the advantages that the recombinant adeno-associated virus WNT9B can be used for promoting myocardial regeneration; the immune response caused by the recombinant adeno-associated virus WNT9B after injection is weak and short. The recombinant adeno-associated virus WNT9B adopts an adeno-associated virus vector carrying a cardiac muscle cell specific promoter cTNT, and when AAV successfully transfects cardiac muscle tissues, only cardiac muscle cells can start the vector to express an exogenous Wnt9b gene, so that cell specific treatment is realized.